Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
The purpose of this study is to determine whether brivanib is an effective treatment for liver cancer in Asian patients who have failed or could not tolerate sorafenib therapy.
Carcinoma, Hepatocellular
DRUG: Brivanib|DRUG: Placebo
Compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to sorafenib and receive brivanib plus best supportive care (BSC) to those receiving placebo plus BSC, Every 6 weeks for an average of 6 months
Compare time to progression (TTP) using modified RECIST for HCC, Every 6 weeks|Compare objective response rate (ORR) and disease control rate (DCR) using modified RECIST for HCC, Every 6 weeks|Assess duration of response, duration of disease control and time to response, Every 6 weeks|Assess serious and nonserious adverse events, laboratory evaluations, significant physical examination findings and ECG results, Every 6 weeks
The purpose of this study is to determine whether brivanib is an effective treatment for liver cancer in Asian patients who have failed or could not tolerate sorafenib therapy.